Ikonisys
Finding the cells that matter
Finding the cells that matter
Ikonisys is a biotechnology and health care startup founded in 1999 with the slogan "Finding the cells that matter." The company is dedicated to transforming diagnostic medicine through early, accurate, and non-invasive disease detection. Its flagship product, the Ikoniscope20®, is a breakthrough fluorescence microscopy platform that automates traditional FISH-based tests and offers rare cell detection and analysis capabilities for examining large and complex samples for clinically relevant cells.
The company has received a €150.00K post-IPO equity investment on 04 June 2024, showcasing investor confidence in its innovative technology. Despite being headquartered in France, the company has not disclosed the details of the last investment investors.
With a focus on developing oncology tests for various cancers, Ikonisys is at the forefront of utilizing technology and science to provide high-quality cell images and accurate analysis, enabling quick and precise reporting of test results. By enabling physicians and researchers to harness the potential of rare cell detection, Ikonisys aims to improve patient outcomes and disease management.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | €150.00K | - | 04 Jun 2024 |
No recent news or press coverage available for Ikonisys.
We care about your data, and we'd love to use cookies make your experience better.
